Biocorrx (OTCMKTS:BICX) Issues Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Biocorrx (OTCMKTS:BICX) issued its quarterly earnings results on Friday. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.05), Zacks reports.

Biocorrx Stock Performance

Shares of Biocorrx stock traded up $0.01 on Friday, hitting $0.45. The company’s stock had a trading volume of 2,003 shares, compared to its average volume of 5,162. The firm has a fifty day moving average price of $0.40 and a 200-day moving average price of $0.37. The company has a market capitalization of $9.07 million, a price-to-earnings ratio of -1.28 and a beta of 0.07. Biocorrx has a 1 year low of $0.20 and a 1 year high of $1.45.

Analysts Set New Price Targets

Separately, Zacks Research raised shares of Biocorrx to a “hold” rating in a report on Tuesday, September 2nd. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock currently has a consensus rating of “Hold”.

About Biocorrx

BioCorRx Inc, through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition.